Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report sent to investors on Tuesday morning. The brokerage issued an equal weight rating and a $5.00 target price on the stock.

Zentalis Pharmaceuticals Trading Up 0.7%

NASDAQ:ZNTL opened at $2.73 on Tuesday. The company has a market cap of $197.24 million, a price-to-earnings ratio of -1.32 and a beta of 1.71. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $3.95. The stock has a fifty day simple moving average of $2.68 and a 200-day simple moving average of $1.90.

Insider Buying and Selling

In related news, insider Vincent Vultaggio sold 29,951 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. The trade was a 16.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Group Walters acquired 6,459,973 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the purchase, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have sold 46,617 shares of company stock worth $113,417. Corporate insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Sivia Capital Partners LLC purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $27,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $31,000. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $41,000. SG Americas Securities LLC increased its holdings in Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after buying an additional 8,236 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new stake in Zentalis Pharmaceuticals during the second quarter worth $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.